Difference between revisions of "Fujiwara Y, et al. Cancer Sci. (2019) cited as Ref 640 in DOI: 10.1038/s41392-020-0110-5 (Q9903)"
Jump to navigation
Jump to search
(Added link to [sliswiki]: Fujiwara Y, et al. Cancer Sci. (2019) cited as Ref 640 in DOI: 10.1038/s41392-020-0110-5, #quickstatements; #temporary_batch_1589988087154) |
(Created claim: Page(s) (P105): 1715-1723, #quickstatements; #temporary_batch_1590074839150) |
||||||||||||||
(7 intermediate revisions by the same user not shown) | |||||||||||||||
Property / First Author string | |||||||||||||||
+ | Fujiwara Y | ||||||||||||||
Property / First Author string: Fujiwara Y / rank | |||||||||||||||
+ | Normal rank | ||||||||||||||
Property / DOI Identifier | |||||||||||||||
+ | |||||||||||||||
Property / DOI Identifier: 10.1111/cas.14003 / rank | |||||||||||||||
+ | Normal rank | ||||||||||||||
Property / PubMed ID | |||||||||||||||
+ | |||||||||||||||
Property / PubMed ID: 30891877 / rank | |||||||||||||||
+ | Normal rank | ||||||||||||||
Property / Publication Date | |||||||||||||||
+ | 2019
| ||||||||||||||
Property / Publication Date: 2019 / rank | |||||||||||||||
+ | Normal rank | ||||||||||||||
Property / Published In Name String | |||||||||||||||
+ | Cancer Sci. | ||||||||||||||
Property / Published In Name String: Cancer Sci. / rank | |||||||||||||||
+ | Normal rank | ||||||||||||||
Property / Volume | |||||||||||||||
+ | 110 | ||||||||||||||
Property / Volume: 110 / rank | |||||||||||||||
+ | Normal rank | ||||||||||||||
Property / title | |||||||||||||||
+ | Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors (English) | ||||||||||||||
Property / title: Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors (English) / rank | |||||||||||||||
+ | Normal rank | ||||||||||||||
Property / Page(s) | |||||||||||||||
+ | 1715-1723 | ||||||||||||||
Property / Page(s): 1715-1723 / rank | |||||||||||||||
+ | Normal rank |
Latest revision as of 15:47, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language | Label | Description | Also known as |
---|---|---|---|
English |
Fujiwara Y, et al. Cancer Sci. (2019) cited as Ref 640 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Fujiwara Y
0 references
2019
0 references
Cancer Sci.
0 references
110
0 references
Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors (English)
0 references
1715-1723
0 references